Finvest
HSIC Health Care Distribution · Dental · Medical supplies · Health tech · Thesis updated July 12, 2026

Dental distribution, with software upside

01 Running thesis

A better first read

Henry Schein is a large middleman for dental and medical offices. It sells the everyday supplies dentists and doctors use, plus equipment, dental specialty products, and software. The latest quarter gave investors a clearer first look at the company under new CEO Fred Lowery.

The bull case improved after Q1 2026. Revenue was $3.37 billion, up 6.3% year over year, and non-GAAP diluted EPS was $1.32, up 14.8%. Management also kept its full-year 2026 outlook for 3% to 5% total sales growth and $5.23 to $5.37 in non-GAAP diluted EPS.

The better story is in software. More than 13,000 practices now subscribe to Henry Schein's cloud dental software, with the user count up about 25% year over year. New AI products could add another growth lane if customers pay for them and if margins expand.

The bear case is still real. Most sales still come from distribution, where costs, pricing, inventory, and customer demand matter a lot. Medical demand softened because respiratory test products were weaker, and the company still has to prove that its efficiency plan and recent deals can raise profit without hurting service.

May 2026Q1 2026 filled the prior information gap with $3.37 billion of revenue, $1.32 of non-GAAP diluted EPS, and reaffirmed full-year guidance. The cloud software base passed 13,000 practices, which strengthened the growth case.
May 2026The Q1 2026 Form 10-Q added useful segment detail but did not add a fresh risk factor discussion. The filing showed three reportable segments for the period.
Feb 2026The 2025 Form 10-K could not be parsed in the internal workflow, so it did not resolve the earlier disclosure questions. The thesis stayed cautious pending cleaner source data.
Nov 2025The initial internal thesis was built from financial statement notes because the Q3 2025 filing lacked a usable management narrative. The base view was stable but information was limited.
02 Business model

Supplies first, software next

Henry Schein makes most of its money by buying, warehousing, and selling health care products to office-based dental and medical providers. These products include dental supplies, infection-control items, vitamins, pharmaceuticals, vaccines, diagnostic tests, and equipment.

The company also sells higher-value dental specialty products, such as implants, biomaterials, orthodontics, and endodontic products. These can be more attractive than basic distribution because they are more specialized and less like a simple commodity.

Software is the smaller but more interesting piece. Henry Schein sells practice management software, e-services, and other tools to health care providers. Cloud subscriptions and AI products give the company a path to more recurring revenue, but the filing and earnings summary do not yet show the annual recurring revenue or margin profile.

This model can break if dentists and doctors see fewer patients, if customers buy fewer big-ticket equipment items, if product demand swings after a health cycle, or if cost inflation outpaces price increases. It can also break if software growth stays small compared with the much larger distribution base.

03 Product portfolio

What offices buy

Cash cow

Dental merchandise and consumables

This includes dental supplies, infection-control products, PPE, handpieces, composites, anesthetics, and other everyday items. It is the core volume business.

Steady

Dental equipment and repair

Henry Schein sells dental chairs, delivery units, lights, X-ray equipment, digital lab tools, and related repair services. Equipment can be more cyclical because offices can delay large purchases.

Steady

Medical distribution

The medical side sells branded and generic drugs, vaccines, surgical products, diagnostic tests, and related supplies. Q1 2026 showed some weakness tied to lower demand for respiratory test products.

Growth engine

Dental specialty products

This group includes dental implants, biomaterials, endodontic, orthodontic, and orthopedic products. Recent M&A is meant to build out these specialty offerings.

Growth engine

Practice management software

The cloud dental software platform now serves more than 13,000 subscribing practices. That base grew about 25% year over year in Q1 2026.

Option

AI products and e-services

Management called out new AI product launches as part of the Technology momentum. The open question is how these tools will be priced and how much profit they can add.

04 Business segments

Three reported pieces

Global Distribution and Value-Added Services84%modest
Global Specialty Products11%modest
Global Technology5%growing fast

The segment mix uses net sales from the Q1 2026 Form 10-Q for the three months ended March 28, 2026. Global Distribution and Value-Added Services is much larger than the other two segments, so small changes there can outweigh faster growth in software.

05 Risk factors

What could go wrong

Medical product cycle fades

Medium impact · Medium odds

The Medical business was soft in Q1 2026 because demand for respiratory test products fell. That shows part of the business can swing with health cycles rather than only steady office demand. If another product category rolls over, sales growth could miss guidance.

We watchGlobal Medical sales growth and management comments on respiratory tests or diagnostic test demand.

Software stays too small

Medium impact · Medium odds

Cloud dental software and AI products are the clearest upside story, but Global Technology was only about 5% of Q1 2026 net sales. The company has disclosed more than 13,000 cloud subscribers, but not the annual recurring revenue or margin profile. If monetization is weak, the software story may not move total company profit much.

We watchCloud subscriber growth, disclosed ARR, Technology segment sales, and Technology segment operating income.

Efficiency plan misses

High impact · Medium odds

Management is targeting $125 million of operating income improvement by year-end 2026 as part of a larger $200 million plan. The company also recorded $12 million of restructuring and related costs in Q1 2026. If savings come late or service quality slips, the plan could fail to lift earnings.

We watchProgress against the $125 million 2026 target, restructuring costs, operating margin, and customer service commentary.

Debt and receivables pressure

Medium impact · Low odds

Henry Schein uses bank credit lines, long-term debt, and a U.S. trade accounts receivable securitization facility. The Q1 2026 filing says late customer payments or nonpayment could reduce borrowing ability under the receivables facility. Higher rates or weaker collections would tighten flexibility.

We watchAccounts receivable trends, operating cash flow, borrowing under the receivables facility, and interest expense.

M&A integration drag

Medium impact · Medium odds

The company keeps buying businesses to add products, customers, and geography. In Q1 2026 it acquired companies in Global Distribution and Value-Added Services and Global Specialty Products, with total consideration of $93 million. If integrations are messy, goodwill, costs, or distraction could offset the growth benefits.

We watchAcquisition spending, goodwill, restructuring charges, and Specialty Products operating income.
06 Quick answers

In one breath

What does Henry Schein do?

Henry Schein sells supplies, equipment, specialty dental products, and software to dental and medical offices. It is mainly a health care distributor, with a smaller but growing technology segment.

Is Henry Schein mainly a dental company?

Dental is a large part of the company, but not the only part. The Q1 2026 filing also shows a Global Medical business inside distribution, plus separate Global Specialty Products and Global Technology segments.

Why does software matter for HSIC stock?

Software can be more recurring than product distribution because practices subscribe to tools they use every day. Henry Schein says more than 13,000 practices use its cloud dental software, but investors still need more detail on revenue and margins.

What should investors watch next?

Watch whether management delivers the $125 million operating income improvement target by year-end 2026. Also watch cloud software subscribers, AI pricing, Medical sales trends, and whether full-year EPS guidance holds.